ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Clinical trial NCT02737501 · COMPLETED
Trial details
- NCT number
- NCT02737501
- Sponsor
- Ariad Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-26
- Primary completion
- 2020-07-28
- Enrollment
- 275
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.